Larry D. Anderson, Jr, MD, PhD | Authors


Rationale, Data, and Future of Using Ide-Cel CAR T-Cell Therapy

September 01, 2021

Larry D. Anderson, Jr, MD, PhD, discusses the rationale behind using chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma, data from the KarMMa trial, and other trials investigating this treatment.